In the first quarter of 2025, the welding therapy agency reports financial results and the latest business highlights

The company expands the cash pipes in 2028

London (business wire)-$ Sln #Senseofsilence-Silence Therapeutics PLC, Nasdaq: SLN (“Silence” or “The company”), a global company on a clinical level, which develops new Sirna therapies (Short Interfering RNA), reported today about its financial results for the first quarter on March 31, 2025 and reviewed the recent commercial highlights.

“The silence delivered another strong quarter that focused on clinical and operational execution,” said Craig Tooman, President and Chief Executive Officer from Silence. “We continue to concentrate on promoting the enrollment in the Saneco Phase 2 study by Divesiran, a first-class Sirna program in PV and continued to be on the track by the end of this year.

Rhonda Hellums, Chief Financial Officer from Silence, added: “We ended the first quarter with over $ 136 million in cash, cash equivalents and short-term investments. To maintain a healthy financial position and at the same time prioritize the further development of our core program. improve. ”

First quarter 2025 and the latest business highlights

Divesiran for Polycythemia Vera (PV)

Additional phase -1 results from the Divesiran Saneco study at PV patients were accepted for oral presentation during the annual congress of European hematology (EHA) 2025 from June 12th to 15th, 2025 in Milan.
Advanced patient admission to the proportion of phase 2 of the Divesiran Saneco study in PV patients and fall by route by the end of 2025.

Zerlasiran for cardiovascular diseases

Advanced Core Phase 3 Readiness activities, including manufacturing and supply scale, which will remain on the way by mid-2025. Partner discussions for the potential development of phase 3 have not yet been completed.

Cooperation

A phase -1 study by SLN312 (licensed to AstraZeneca) has not yet been completed.

Corporate updates

Tim Mcinerney was appointed to the company's board of directors on May 5, 2025. Mr. Mcinerney is an experienced executive and board member with over 30 years of experience both in the investment and in the pharmaceutical industry.

First quarter 2025 financial highlights

Cash position: Cash and cash equivalent and short -term investments of $ 136.5 million on March 31, 2025, compared to $ 147.3 million on December 31, 2024.
F&E editions: Research and development costs (F&E) amounted to $ 20.8 million, an increase of $ 9.0 million compared to the first quarter of 2024. The increase was primarily due to the further development of our clinical studies and an increase in manufacturing activities for our proprietary programs.
G&A editions: The general and administrative (G&A) expenditure was $ 7.7 million, an increase of USD 1.0 million compared to the first quarter of 2024.
Net lust: The net loss was $ 28.5 million or $ 0.20 and diluted net loss per share compared to a net loss of $ 2.3 million or a basic and watered net loss per share in the first quarter of 2024.
From March 31, 2025, the overall outstanding ADS was around 47,230,283.

Updates of the financial guidance of 2025

Silence has carried out cost saving initiatives to strengthen its financial situation and further extend its cash landing railway in 2028. These measures include general and administrative reductions as well as the further prioritization of research projects and resources in the early stages. The company is still obliged to recognize the enormous potential of its proprietary Mrnai Gold ™ platform and will continue to invest in important areas that concentrate on increasing the value for stakeholders to silence.

About silent therapeutic agents

Silence Therapeutics is a global biotechnology company for clinical level that is committed to changing people's lives by causing diseases through precision-led medicines with proprietary Sirna technology (short interfering RNA). The silence uses its Mrnai Gold ™ platform to create innovative Sirnas that aim to target disease genes in the liver and to remain silent, which is an essential opportunity. The silence focuses on areas with a high, not fulfilled medical needs with programs that progress in cardiovascular diseases, hematology and rare diseases. You can find more information under Viewing https://www.silenz- therapeutics.com/.

Predicted statements

This press release contains future -oriented statements within the meaning of Section 27a of the Securities Act of 1933 in the changed version and § 21e of the Securities Exchange Act from 1934 in the changed version. In some cases, you can identify forward-looking statements by Terminology Such as “Aim,” “Anticipate,” “Assume,” “Believe,” “Contemplate,” “Continue,” ““ Design, ”“ Due, ”“ Estimate, ”“ EXPECT, ”“ INTEND, ”” “Objective,” “Plan,” “Positioned,” “Potential,” “Seek,” “Should,” “Target,” “Will”, “Dignity”, “Dignity”, the future events and future trends or the negative of these terms or other comparable terminology. All other statements than statements from historical facts contained in this press release are future -oriented statements. These future -oriented statements include statements: the company's business strategy and plans, including the company's clinical development activities and periods; Progress and progress of collaborations; the expected advantages of the company's cost saving initiatives; the company's ability to improve the value of stakeholders; And the expected longer cash ram of the company. Future -oriented statements are not guarantees for future performance and are subject to risks and uncertainties that can lead to the fact that actual results and events significantly from those expected, including, but not limited to risks and uncertainties related to: the history of the company of net loss; the company's ability to receive the necessary capital to finance its clinical programs; The early phases of the company's clinical development of the company's product candidates; the company's ability to approve and successfully commercialize its product candidates; All unwanted side effects or other properties of the company's product candidates; the dependence of the company on suppliers and manufacturers of third -party providers; the results of future collaboration agreements; And the company's ability to adequately maintain the rights to intellectual property for its product candidates. These and other risks are described in more detail as part of the section with the title “Risk Factors”, which are reported in the company's annual report on form 10-K and quarterly on form 10-Q and the other submissions of the company at the Sec. All future-oriented statements that the company submits in this press release are made in the changed version in accordance with the private Verwaffle dispute Reform Act of 1995 and only speak at the time of this press release. If legally prescribed by law, the company assumes no obligation to publicly update future statements, be it based on new information, future events or otherwise.

Silent therapeutics PLC
Concert consolidated balance sheets
(Unchecked, in thousands, except Share and Per -Share data)

	Period ended
	March 31, 2025			December 31, 2024
Circulation
Cash and cash equivalent	$	64,886		$	121,330
Short -term investments		71,648			26.004
Research and development recipient		16,796			24,396
Other current assets		16.419			14,664
Commercial research		41			972
Total power assets		169,790			187,366
Property, system and equipment		1.693			1.818
Business attorney		107			157
Goodwill		9.784			9.392
Other intangible assets		310			312
Other long -term assets		3.614			3.590
Total assets	$	185.298		$	202.635

Current liabilities
Contract liabilities	$	(392	)))	$	(306	)))
Trade and other liabilities		(18,812	)))		(16,399	)))
Operating leasing liabilities, currently		(60	)))		(117	)))
Total current liabilities		(19.264	)))		(16,822	)))
Contract liabilities		(53.291	)))		(51,790	)))
Total liabilities	$	(72,555	)))	$	(68,612	)))
Commitments and eventualities (note 20)

Equity of shareholders
Chief shares – nominal value £ 0.05 per share; 141,690,850 shares Exhibited on March 31, 2025 (December 31, 2024: 141,674.074)		(10.289	)))		(10.288	)))
Additional paid capital		(613.074	)))		(609,560	)))
Accumulated deficit		502.536			474.044
Accumulated other comprehensive losses		8.084			11,781
Equity of shareholders		(112,743	)))		(134.023	)))

Overall liabilities and shareholders equity	$	(185.298	)))	$	(202.635	)))

Silent therapeutics PLC
Concert consolidated surgical statements and comprehensive losses
(Unchecked, in thousands, except Share and Per -Share data)

	Three months ended on March 31,
	2025			2024
revenue	$	142		$	15,699
Sales costs		(54	)))		(2,800	)))
Gross profit		88			12,899
Research and development costs		(20.813	)))		(11.845	)))
General and administrative costs		(7.684	)))		(6.635	)))
Operating loss		(28.409	)))		(5,581	)))
Foreign currency (loss)/profit, network		(3,769	)))		351
Other income, network		969			667
Benefit from F&E credit		2.679			2.495
Loss of income tax expenses		(28:530	)))		(2,068	)))
Income tax effort		–			(244	)))
Net	$	(28:530	)))	$	(2,312	)))
Loss per share (basic and watered down)	$	(0.20	)))	$	(0.02	)))

Contacts

Inquiries:

Silent therapeutics PLC
Gem Hopkins, VP, IR and corporate communication

ir@silece- therapeutics.com
Tel: +1 (646) 637-3208

Leave a Comment Cancel reply